(a) (i) Elaborate the indications for initiating antiviral therapy in a patient with chronic hepatitis B.
(ii) Write the first-line antivirus treatment regimen for the management of chronic hepatitis B along with the recommended monitoring strategy d

Question

(a) (i) Elaborate the indications for initiating antiviral therapy in a patient with chronic hepatitis B.
(ii) Write the first-line antivirus treatment regimen for the management of chronic hepatitis B along with the recommended monitoring strategy during therapy. 10+15=25
(b) Write the risk factors for respiratory distress syndrome (RDS) in newborn. What is the differential diagnosis of RDS? How will you manage respiratory distress syndrome in newborn? 5+5+5=15
(c) A 28-year-old female with a long history of psoriasis develops symmetrical, flexural and grouped pustules with high grade fever and severe constitutional symptoms in the third trimester.
(i) What is your diagnosis?
(ii) How do you manage the condition?
(iii) What are the complications? 3+4+3=10

UPSC Answer Check · Accepted Answer

The directive 'elaborate' in (a) demands comprehensive, detailed exposition with supporting evidence. Allocate approximately 50% of time/words to part (a) given its 25 marks, 30% to part (b) for 15 marks, and 20% to part (c) for 10 marks. Structure: begin with concise definitions, then systematically address each sub-part with clinical reasoning, evidence-based protocols, and prognostic considerations. Conclude with integrated take-home messages across the three clinical scenarios.
- (a)(i) Indications for antiviral therapy: HBeAg-positive/negative with elevated ALT (>2× ULN) and HBV DNA >20,000/2,000 IU/mL respectively; cirrhosis with detectable HBV DNA regardless of ALT; family history of HCC/cirrhosis; significant fibrosis (≥F2 by FibroScan/APRI)
- (a)(ii) First-line regimens: Tenofovir disoproxil fumarate (TDF) 300mg OD or Entecavir 0.5mg OD (naïve)/1mg OD (lamivudine-experienced); monitoring: HBV DNA q3-6mo, HBeAg/anti-HBe, ALT, creatinine/eGFR, phosphate (TDF), HBsAg loss annually; resistance testing if virologic breakthrough
- (b) RDS risk factors: prematurity (<34 weeks), maternal diabetes, elective C-section without antenatal steroids, male sex, perinatal asphyxia, second twin; Differential: TTN, sepsis/pneumonia, congenital heart disease (PDA/CHD), meconium aspiration, pulmonary hemorrhage; Management: CPAP, surfactant (poractant alfa 100mg/kg), ventilatory support, supportive care
- (c)(i) Diagnosis: Impetigo herpetiformis (pustular psoriasis of pregnancy) – characteristic flexural grouped pustules, fever, hypocalcemia risk; differentiate from acute generalized pustular psoriasis and pustular drug eruption
- (c)(ii) Management: Prompt delivery if near term; systemic corticosteroids (prednisolone 0.5-1mg/kg), cyclosporine as steroid-sparing; supportive care (fluids, electrolytes, calcium repletion); dermatology-obstetrics joint care
- (c)(iii) Complications: Maternal – hypocalcemia, sepsis, placental insufficiency, preterm labor; Fetal – IUGR, stillbirth, neonatal sepsis; recurrence risk in subsequent pregnancies

Dimension	Weight	Max marks	Excellent	Average	Poor
Concept correctness	20%	10	Precise EASL/AASLD guideline-based thresholds for therapy initiation in (a); accurate gestational age-specific surfactant physiology in (b); correct distinction of impetigo herpetiformis from other pustular eruptions with pathognomonic histology (subcorneal pustules, spongiform pustules of Kogoj) in (c)	Broadly correct indications but imprecise cut-offs (e.g., missing HBV DNA thresholds); generic RDS pathophysiology without specific risk stratification; recognizes pustular eruption in pregnancy but confuses with acute GPP or fails to name impetigo herpetiformis	Fundamental errors: incorrect first-line agents (e.g., lamivudine as first-line), missing virologic monitoring; conflates RDS with TTN or misses major differentials; misdiagnoses as bacterial impetigo or allergic eruption with inappropriate antibiotic focus
Clinical correlation	20%	10	Integrates Indian epidemiology (vertical transmission dominance, HBsAg prevalence 2-4%); links maternal betamethasone administration timing to RDS prevention; discusses pregnancy-specific drug safety (TDF preferred in pregnancy, entecavir teratogenicity concerns; cyclosporine vs. biologics in impetigo herpetiformis)	Mentions standard protocols without contextual adaptation; acknowledges pregnancy constraints superficially; limited discussion of resource-limited settings or Indian national immunization program (Hepatitis B birth dose)	Generic textbook recitation without clinical application; ignores pregnancy-specific pharmacokinetics and safety; fails to address vertical transmission prevention or neonatal Hepatitis B immunoprophylaxis
Diagram / pathway	15%	7.5	Clear algorithm for chronic Hepatitis B treatment decision-making (HBeAg status → ALT/HBV DNA → fibrosis assessment → treatment); surfactant synthesis pathway diagram; clinical photograph-level description of flexural pustular distribution in impetigo herpetiformis	Mentions need for algorithms without clear depiction; describes surfactant deficiency mechanism textually; vague description of skin lesions without anatomic localization	No structured representation; missing diagrams where essential (e.g., natural history phases of chronic HBV); no visual or descriptive clarity for dermatologic diagnosis
Differential / staging	20%	10	Systematic differentials: for RDS – clinical/radiological distinction from TTN (symmetry, clearing by 72h), sepsis (risk factors, cultures), CHD (pre-ductal SpO2 differential, echocardiography); for pustular eruption – histopathological differentiation from subcorneal pustular dermatosis, IgA pemphigus, acute GPP triggers	Lists differentials without discriminating features; mentions major alternatives but misses key distinguishing investigations (e.g., echocardiography for CHD, blood cultures for sepsis)	Incomplete or incorrect differentials; misses life-threatening mimics (sepsis, pulmonary hemorrhage in RDS; acute fatty liver of pregnancy in (c))
Management / public-health angle	25%	12.5	Evidence-based stepwise approach: (a) TDF with renal monitoring, stopping rules (consolidated vs. indefinite per HBeAg status); (b) INSURE technique (Intubation-SURfactant-Extubation to CPAP), gentle ventilation strategies, caffeine; (c) multidisciplinary management with delivery timing, high-dose steroids, calcium monitoring; includes Hepatitis B prevention (birth dose vaccine + HBIG within 24h) and RDS prevention (antenatal corticosteroids, MgSO4 for neuroprotection)	Standard management without nuance (e.g., missing INSURE, not specifying surfactant dosing); generic steroid use in pregnancy without tapering plan; superficial prevention strategies	Outdated or unsafe practices (interferon in pregnancy, lamivudine monotherapy, immediate mechanical ventilation without CPAP trial); misses emergency delivery indication in impetigo herpetiformis; no preventive health integration

Q3

Directive word: Elaborate

How this answer will be evaluated

Approach

Key points expected

Evaluation rubric

Practice this exact question

More from Medical Science 2025 Paper II